Which has higher valuation and earnings, FLNA or CRDL?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A

Is FLNA or CRDL more profitable?

Cassava Sciences' return on equity of -58.78% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Cardiol Therapeutics N/A -180.44% -140.28%

Does the media favor FLNA or CRDL?

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.91 beat Cardiol Therapeutics' score of 0.87 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, NERV or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is NERV or FLNA more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Cassava Sciences N/A -58.78% -36.74%

Do analysts rate BGM or FLNA?

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 557.20%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, BGM or FLNA?

BGM Group has higher revenue and earnings than Cassava Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 3.01 -$19.94M N/A N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is BGM or FLNA more profitable?

BGM Group's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Cassava Sciences N/A -58.78% -36.74%

Does the media favor FLNA or NRXP?

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.91 beat NRx Pharmaceuticals' score of 0.60 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTVT or FLNA more profitable?

vTv Therapeutics' return on equity of -6.27% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Cassava Sciences N/A -58.78% -36.74%

Does the media prefer VTVT or FLNA?

In the previous week, vTv Therapeutics had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 6 mentions for vTv Therapeutics and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.91 beat vTv Therapeutics' score of 0.26 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cassava Sciences (FLNA) Competitors

$0.70 -0.06 (-7.53%)

As of 04:00 PM Eastern

Compare

FLNA vs. CRDL, NERV, BGM, NRXP, and VTVT

Should you buy Cassava Sciences stock or one of its competitors? Cassava Sciences's main competitors and comparable companies include Cardiol Therapeutics (CRDL), Minerva Neurosciences (NERV), BGM Group (BGM), NRx Pharmaceuticals (NRXP), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cassava Sciences compare to Cardiol Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 557.20%. Cardiol Therapeutics has a consensus target price of $10.00, indicating a potential upside of 769.57%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.91 beat Cardiol Therapeutics' score of 0.87 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cassava Sciences' return on equity of -58.78% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Cassava Sciences has a beta of -0.65, meaning that its share price is 165% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Summary

Cardiol Therapeutics beats Cassava Sciences on 8 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Minerva Neurosciences presently has a consensus price target of $10.33, indicating a potential upside of 327.00%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 557.20%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Cassava Sciences	N/A	-58.78%	-36.74%

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

In the previous week, Cassava Sciences had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Minerva Neurosciences. Cassava Sciences' average media sentiment score of 0.91 beat Minerva Neurosciences' score of 0.60 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Minerva Neurosciences	Positive
Cassava Sciences	Positive

Minerva Neurosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.65, indicating that its stock price is 165% less volatile than the broader market.

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cassava Sciences beats Minerva Neurosciences on 7 of the 10 factors compared between the two stocks.

How does Cassava Sciences compare to BGM Group?

BGM Group (NASDAQ:BGM) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

BGM Group has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.65, indicating that its stock price is 165% less volatile than the broader market.

BGM Group's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Cassava Sciences	N/A	-58.78%	-36.74%

38.1% of Cassava Sciences shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 557.20%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BGM Group and BGM Group both had 2 articles in the media. Cassava Sciences' average media sentiment score of 0.91 beat BGM Group's score of 0.39 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Neutral
Cassava Sciences	Positive

BGM Group has higher revenue and earnings than Cassava Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	3.01	-$19.94M	N/A	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Summary

BGM Group beats Cassava Sciences on 6 of the 11 factors compared between the two stocks.

How does Cassava Sciences compare to NRx Pharmaceuticals?

Cassava Sciences (NASDAQ:FLNA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Cassava Sciences has a beta of -0.65, meaning that its stock price is 165% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.91 beat NRx Pharmaceuticals' score of 0.60 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NRx Pharmaceuticals has higher revenue and earnings than Cassava Sciences. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
NRx Pharmaceuticals	$1.23M	95.40	-$28.62M	-$0.55	N/A

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 557.20%. NRx Pharmaceuticals has a consensus price target of $34.50, indicating a potential upside of 1,173.06%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cassava Sciences has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Cassava Sciences on 10 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

vTv Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.65, suggesting that its stock price is 165% less volatile than the broader market.

vTv Therapeutics' return on equity of -6.27% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Cassava Sciences	N/A	-58.78%	-36.74%

vTv Therapeutics has higher revenue and earnings than Cassava Sciences. vTv Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	106.57	-$26.97M	-$1.06	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

In the previous week, vTv Therapeutics had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 6 mentions for vTv Therapeutics and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.91 beat vTv Therapeutics' score of 0.26 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics currently has a consensus target price of $55.83, suggesting a potential upside of 102.37%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 557.20%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

vTv Therapeutics beats Cassava Sciences on 10 of the 14 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.75M	$12.62B	$7.36B	$12.64B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	N/A	802.67	274.15	24.84
Price / Sales	N/A	937.23	624.75	97.88
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	0.46	9.21	10.29	5.86
Net Income	-$90.97M	$2.85B	$3.50B	$380.67M
7 Day Performance	-13.87%	-5.08%	-5.37%	-4.97%
1 Month Performance	2.82%	-8.21%	-8.55%	-6.95%
1 Year Performance	-84.44%	-5.57%	0.43%	-5.99%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	3.52 of 5 stars	$0.70 -7.5%	$5.00 +610.7%	-83.6%	$36.75M	N/A	N/A	30	Gap Down
CRDL Cardiol Therapeutics	3.4497 of 5 stars	$1.24 +0.4%	$10.00 +709.7%	+6.5%	$146.88M	N/A	N/A	18	News Coverage
NERV Minerva Neurosciences	1.7266 of 5 stars	$2.94 -7.7%	$10.33 +252.0%	-3.6%	$141.15M	N/A	N/A	7
BGM BGM Group	0.5097 of 5 stars	$10.13 -5.8%	N/A	-96.7%	$128.52M	$47.90M	N/A	471	Short Interest Increase
NRXP NRx Pharmaceuticals	2.1902 of 5 stars	$2.91 +1.9%	$34.50 +1,087.6%	-14.5%	$125.79M	$1.23M	N/A	29	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. CRDL, NERV, BGM, NRXP, and VTVT

How does Cassava Sciences compare to Cardiol Therapeutics?

Summary

How does Cassava Sciences compare to Minerva Neurosciences?

Summary

How does Cassava Sciences compare to BGM Group?

Summary

How does Cassava Sciences compare to NRx Pharmaceuticals?

Summary

How does Cassava Sciences compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. CRDL, NERV, BGM, NRXP, and VTVT

How does Cassava Sciences compare to Cardiol Therapeutics?

Do analysts prefer FLNA or CRDL?

Do insiders & institutionals have more ownership in FLNA or CRDL?

Does the media favor FLNA or CRDL?

Is FLNA or CRDL more profitable?

Which has more risk and volatility, FLNA or CRDL?

Which has higher valuation and earnings, FLNA or CRDL?

Summary

How does Cassava Sciences compare to Minerva Neurosciences?

Do analysts prefer NERV or FLNA?

Is NERV or FLNA more profitable?

Which has better earnings & valuation, NERV or FLNA?

Does the media refer more to NERV or FLNA?

Which has more volatility and risk, NERV or FLNA?

Do insiders and institutionals believe in NERV or FLNA?

Summary

How does Cassava Sciences compare to BGM Group?

Which has more risk and volatility, BGM or FLNA?

Is BGM or FLNA more profitable?

Do institutionals & insiders have more ownership in BGM or FLNA?

Do analysts rate BGM or FLNA?

Does the media prefer BGM or FLNA?

Which has preferable valuation and earnings, BGM or FLNA?

Summary

How does Cassava Sciences compare to NRx Pharmaceuticals?

Which has more risk and volatility, FLNA or NRXP?

Does the media favor FLNA or NRXP?

Which has better valuation and earnings, FLNA or NRXP?

Do analysts prefer FLNA or NRXP?

Is FLNA or NRXP more profitable?

Do insiders & institutionals have more ownership in FLNA or NRXP?

Summary

How does Cassava Sciences compare to vTv Therapeutics?

Do insiders and institutionals hold more shares of VTVT or FLNA?

Which has more volatility and risk, VTVT or FLNA?

Is VTVT or FLNA more profitable?

Which has stronger valuation & earnings, VTVT or FLNA?

Does the media prefer VTVT or FLNA?

Do analysts prefer VTVT or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools